Abstract: Pharmaceutical compositions comprising nitroxoline lysinate, a preparation method therefor and a use thereof. The pharmaceutical compositions comprise a first layer and a second layer. The first layer comprises, based on the total weight of the first layer, 40%-70% of active pharmaceutical ingredient, 10%-30% of filler, 5%-12% of disintegrant, 0.5%-2% of lubricant, 0.1%-1.5% of glidant and 10%-20% of alkaline substance. The second layer comprises, based on the total weight of the second layer, 40%-70% of active pharmaceutical ingredient, 10%-30% of filler, 10%-35% of sustained-release material, 0.1%-2% of lubricant and 0.1%-2% of glidant. The active pharmaceutical ingredient is selected from one or more of nitroxoline lysinate, nitroxoline lysinate crystalline form and nitroxoline lysinate solvate. The pharmaceutical compositions can achieve the purpose of burst release at an early stage and sustained and slow release at a later stage.

Abstract: A pharmaceutical composition containing a nitroxoline prodrug, and a preparation method and an application therefor. The pharmaceutical composition comprises the following ingredients in parts by weight: 100 parts of active pharmaceutical ingredient, 22.5-320 parts of filler, 0-40 parts of disintegrant, 0-95 parts of binding agent, and 2-30 parts of lubricant; relative to each 100 parts by weight of active pharmaceutical ingredient, the total content of the filler, the disintegrant, and the binding agent is 54-345 parts by weight; the active pharmaceutical ingredient is (S)-(5-nitroxoline-8-yloxy)methyl 1-isopropylpyrrolidine-2-carboxylate. The pharmaceutical composition has good stability, dissolution properties, and pharmacokinetic characteristics.

Abstract: Disclosed are a pharmaceutical composition containing nitroxoline, a nitroxoline tablet, a preparation method therefor, and a use thereof. The pharmaceutical composition comprises an active pharmaceutical ingredient and a pharmaceutically acceptable carrier, the active pharmaceutical ingredient being nitroxoline or a pharmaceutically acceptable salt thereof, and the active pharmaceutical ingredient having a particle size D90 of 10-100 ?m. The pharmaceutical composition containing nitroxoline can be made into a nitroxoline tablet having an appropriate dissolution rate.

Abstract: A pharmaceutical composition containing nitroxoline for the treatment of bladder cancer, a nitroxoline oral solid tablet, a preparation method therefor and use thereof. The pharmaceutical composition comprises nitroxoline, a filler, a disintegrating agent, a binder, and a lubricant. The lubricant is selected from one or two of sodium dodecyl sulfate and sodium stearyl fumarate. The pharmaceutical composition has a moderate dissolution rate, can avoid the burst release phenomenon, is moisture-proof and impermeable, has good stability, is secure and effective, is convenient to take, has strong patient compliance, and meets the requirements of being an oral solid tablet. The preparation method has stable production process, good reproducibility, easy mass production, and good clinical use value and social benefits.

Abstract: A shift register which allows narrower framing of a display screen includes cascade-connected shift register modules. Each shift register module is electrically coupled to first and second scan lines and outputs scanning signals to the first and the second scan lines in a time-division manner in response to first to fourth clock signals. Each shift register module includes an initial circuit, a reset circuit, a first output circuit, and a second output circuit. The initial circuit receives a trigger signal for activating the shift register module. The initial circuit controls the first output circuit to output a signal to the first scan line based on the first clock signal and controls the second output circuit to output a signal to the second scan line according to the second clock signal.

Abstract: A channel detection system includes an interferometer coupled to a spectrum analyzer to differentiate additive spontaneous emission (ASE) noise from optical channels in a dense wave-division multiplex (DWDM) signal. It is assumed that channels, if present, are centered at frequencies corresponding to a standardized channel grid. The relative delay of the interferometer is chosen to be greater than the coherence time of the ASE noise but less than the coherence time of the channels with the interferometer's free spectral range set to an integer divisor of the channel-to-channel frequency spacing of the grid such that active channels experience a high degree of interference. The phase delay of the interferometer is then adjusted to maximize the interference at each grid-aligned frequency. The spectrum-analyzed outputs are compared (e.g., subtracted from one another and then thresholded) to determine the channels present in the DWDM signal.

Abstract: A channel detection system includes an interferometer coupled to a spectrum analyzer to differentiate additive spontaneous emission (ASE) noise from optical channels in a dense wave-division multiplex (DWDM) signal. It is assumed that channels, if present, are centered at frequencies corresponding to a standardized channel grid. The relative delay of the interferometer is chosen to be greater than the coherence time of the ASE noise but less than the coherence time of the channels with the interferometer's free spectral range set to an integer divisor of the channel-to-channel frequency spacing of the grid such that active channels experience a high degree of interference. The phase delay of the interferometer is then adjusted to maximize the interference at each grid-aligned frequency. The spectrum-analyzed outputs are compared (e.g., subtracted from one another and then thresholded) to determine the channels present in the DWDM signal.

Abstract: The present invention relates in general to SPR sensors in which the sensing element is a planar lightpipe. More specifically, a planar lightpipe sensor configuration for measurement of SPR at a single angle operation is provided. The lightpipe of this sensor is beveled to facilitate coupling of substantially collimated white light, preferably TM polarized white light, at a selected single angle that excites SPR at the sensing area. Angle of incidence on the SPR sensing area is determined by bevel angle used. This embodiment is a zero order sensor in the sense that it allows measurement for a given analyte at only a single angle of incidence. In this embodiment, however, the lightpipe can have a plurality of SPR sensing area across its width to provide for multichannel sensing. Refractive index sensitivity of this configuration is estimated as 4.times.10.sup.-5 RI units.